1. Efficacy and safety of olanzapine in treatment of chronic schizophrenia in  atients not responding to clozapine. (Eli Lilly Company)

2. A multicentre, double blind randomised comparison of dose and dose regimen of seroquel in the treatment of subjects with acute exacerbation of subchronic or chronic schizophrenia (Zeneca pharmaceuticals CNS  international project team)

3. A multicenter randomized double blind active controlled study to compare long-term maintenance effects and afety of aripiprazole and haloperidol following active relapse in schizophrenic patients.  Otsuka Pharmaceutical Co. Ltd.)

4. A multinational multicenter randomized double blind parallel group study to assess the efficacy and safety of one year oral treatment with M100907 versus haloperidol in patients with schizophrenia. (Hoechst Marion Roussel).

5. Treatment of exacerbation of schizophrenia and the effect on cognitive function.

6. First episode- schizophrenia, treatment  esponse and pharmacological mechanism of action.

7. Quality of life of patients with major psychiatric  isorders.

8. Quality of Life in Inpatients Suffering from Severe Mental Disorders: A Longitudinal, Multidimensional, and Cross- Cultural Study

9. A multivariate analysis of novel candidate genes in schizophrenia.

10. A randomized, double- blind, placebo- and active controlled, parallel-group,  ose-
response study to evaluate the
efficacy and safety of 3 fixed
dosages of extended release OROS paliperidone and  lanzapine with open-label extension, in the treatment of subjects with schizophrenia. (Johnson and Johnson  harmaceutical Research and Development, L.L.C.)